Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

מצבים רפואיים

Clonal Cytopenia of Undetermined Significance

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • University of Miami, Miami, Florida, United States

    Contact: Study coordinator (Namrata Chandhok, MD) · nxc691@miami.edu · 305-243-8238
    Contact: Principal Investigator (Namrata S Chandhok, MD)
  • Weill Cornell Medical College, New York, New York, United States

    Contact: Study coordinator (Pinkal Desai, M.D.) · 646-962-2700
    Contact: Principal Investigator (Pinkal Desai, M.D.)
  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Tamanna Haque, MD) · haquet1@mskcc.org · 646-608-4166
    Contact: Principal Investigator (Tamanna Haque, MD)
  • Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Uma M. Borate, MD, MS) · borate.2@osu.edu · 614-293-3316
    Contact: Principal Investigator (Uma M. Borate, MD, MS)
  • Vanderbilt University Medical Center, Nashville, Tennessee, United States

    Contact: Study coordinator (Vanderbilt University Medical Center) · cip@vumc.org · 1-800-811-8480
    Contact: Principal Investigator (Ashwin Kishtagari, MD)
  • UT Southwestern Medical Center at Dallas, Dallas, Texas, United States

    Contact: Study coordinator (Donglan Xia, PhD, BSN) · Donglan.Xia@utsouthwestern.edu · 214-645-9656
    Contact: Study coordinator (Silviya Meletath, MD, MBS) · silviya.meletath@utsouthwestern.edu · 909-560-9597
    Contact: Principal Investigator (Yazan Madanat, MD)
מובילי המחקר
  • Uma M Borate, MD, MS

    Principal Investigator

    Ohio State University Comprehensive Cancer Center